(Total Views: 569)
Posted On: 01/11/2020 4:30:18 PM
Post# of 155791
Who knows, there are new therapies that even reduce CTC but have SAE, this is where Leronlimab is the absolute best.
TYME
"Tyme presented TYME-88-Panc data at the 2019 ASCO GI conference that showed encouraging overall survival "OS" of 6.4 months with a suggestion of attaining stable disease "SD" and a 92% decrease in risk of death. Furthermore, the company reported a decrease in circulating tumor cells "CTCs". Patients who attained a +80% decrease in CTC burden revealed a ~60% reduction in risk of death (Figure 4).
Figure 4: SM-88 CTCs (Source: TYME)
SM-88 has established an encouraging safety profile, with only 4% of the subjects suffering an SM-88 related serious adverse event "SAE". Accordingly, Tyme is preparing to initiate a randomized pivotal trial for SM-88 in pancreatic cancer in Q3 of this year (Figure 5)."
TYME
"Tyme presented TYME-88-Panc data at the 2019 ASCO GI conference that showed encouraging overall survival "OS" of 6.4 months with a suggestion of attaining stable disease "SD" and a 92% decrease in risk of death. Furthermore, the company reported a decrease in circulating tumor cells "CTCs". Patients who attained a +80% decrease in CTC burden revealed a ~60% reduction in risk of death (Figure 4).
Figure 4: SM-88 CTCs (Source: TYME)
SM-88 has established an encouraging safety profile, with only 4% of the subjects suffering an SM-88 related serious adverse event "SAE". Accordingly, Tyme is preparing to initiate a randomized pivotal trial for SM-88 in pancreatic cancer in Q3 of this year (Figure 5)."
(0)
(0)
